drug_type
RELEVANT_DRUG
intervention_type
Radiopharmaceutical (PSMA-targeted small-molecule radioligand)
drug_description
A small-molecule PSMA-targeted beta-emitting radiopharmaceutical. The PSMA ligand binds PSMA (FOLH1) on PSMA-expressing tumor cells, is internalized, and delivers 177Lu beta radiation to induce DNA double-strand breaks and tumor cell death, including a crossfire effect.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Lutetium-177
drug_category
RADIOPEPTIDE CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
PSMA-targeted small-molecule ligand (vipivotide tetraxetan/PSMA-617) chelated to 177Lu binds PSMA on tumor cells, is internalized, and emits beta radiation that induces DNA double-strand breaks, causing tumor cell death with a crossfire effect on adjacent cells.
drug_name
Lutetium-177 vipivotide tetraxetan (Pluvicto)
nct_id_drug_ref
NCT06199453